Mycophenolate Mofetil · oral capsule
Misc.
Approved uses
Prophylaxis of organ rejection in kidney transplantation
1 g twice daily orally or IV in adults; 600 mg/m2 orally twice daily in pediatric recipients 3 months of age and older, up to maximum of 2 g daily
Prophylaxis of organ rejection in heart or liver transplantation
Adults: heart transplant 1.5 g twice daily orally or IV; liver transplant 1.5 g twice daily orally or 1 g twice daily IV. Pediatric patients 3 months and older: 600 mg/m2 orally twice daily (starting dose), up to a maintenance dosage of 900 mg/m2 twice daily (maximum total daily dose of 3 g)
Any patient on this is meaningfully immunosuppressed, which changes how an ocular infection should be read
OFF-LABELNot in the FDA label for this product
Non-infectious uveitis, as a corticosteroid-sparing agent
3 g orally daily in the trial
RCT · n=216 · not superior
The FAST trial randomized 216 adults with non-infectious uveitis to methotrexate 25 mg weekly or mycophenolate 3 g daily. Treatment success at 6 months was 57.1% on mycophenolate against 66.7% on methotrexate, a difference that did not reach significance (odds ratio 1.50, 95% CI 0.81 to 2.81, p=0.20), so mycophenolate was not the better first-line drug overall. Where the two separated was by anatomy: in posterior uveitis and panuveitis methotrexate did better (74.4% against 55.3%, p=0.02), while in intermediate uveitis mycophenolate did (63.6% against 33.3%, p=0.07), with the interaction itself significant at p=0.004. Raised liver enzymes affected 7.4% on mycophenolate.
Non-infectious ocular inflammation, including scleritis and mucous membrane pemphigoid
Oral, as the sole non-corticosteroid agent
Cohort · n=236 · 73% at 1 yr
A retrospective cohort of 236 patients on mycophenolate monotherapy for non-infectious ocular inflammation reached sustained complete control of inflammation in 53% by 6 months and 73% by 1 year, and reduced prednisone to 10 mg a day or less while holding that control in 41% and 55% over the same points. 12% stopped within the first year for side effects, which were typically reversible. The authors' framing is that it works in about half of patients given enough time, so it is a slow agent rather than a rescue one.
Contraindications
- History of hypersensitivity, including anaphylaxis, to mycophenolate mofetil (MMF), mycophenolic acid (MPA) or any component of the drug product
- CellCept Intravenous in patients who are allergic to Polysorbate 80 (TWEEN)
250 mg capsules and 500 mg tablets (bottles of 100, 500); 200 mg/mL oral suspension (225 mL bottle); 500 mg IV single-dose vial (4 vials)
Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of guanosine nucleotide synthesis and blocks DNA synthesis. The mechanism of action of MPA is multifaceted and includes effects on cellular checkpoints responsible for metabolic programming of lymphocytes. MPA shifts transcriptional activities in lymphocytes from a proliferative state to catabolic processes.
Warnings & Precautions
- Embryofetal toxicity: Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations (boxed warning). Avoid if safer treatment options are available. Females of reproductive potential must be counseled regarding pregnancy prevention and planning.
- Lymphoma and other malignancies: Increased risk of development of lymphoma and other malignancies, particularly of the skin (boxed warning). The risk appears to be related to the intensity and duration of immunosuppression. Patients at increased risk for skin cancer should limit exposure to sunlight and UV light with protective clothing and a broad-spectrum sunscreen with a high protection factor.
- Serious infections: Increased susceptibility to bacterial, viral, fungal and protozoal infections, including opportunistic infections and viral reactivation of hepatitis B and C, which may lead to hospitalizations and fatal outcomes (boxed warning). Serious viral infections reported include polyomavirus-associated nephropathy (PVAN), PML, CMV infections and COVID-19. Consider dose reduction or discontinuation if new or reactivated infections develop, weighing the risk of reduced immunosuppression to the allograft.
- Blood dyscrasias: Severe neutropenia developed in transplant patients receiving CellCept 3 g daily, and pure red cell aplasia (PRCA) has been reported in patients treated with CellCept in combination with other immunosuppressive agents. Monitor for neutropenia, and if neutropenia develops (ANC <1.3 × 10^3/µL), interrupt or reduce dosing. Consider complete blood counts weekly for the first month, twice monthly for the second and third months, and monthly for the remainder of the first year.
- Gastrointestinal complications: Gastrointestinal bleeding requiring hospitalization, ulceration and perforations were observed in clinical trials, a concern particularly in patients with a gastrointestinal disease.
- HGPRT deficiency: Avoid in patients with hereditary deficiencies of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndromes, because it may cause an exacerbation of disease symptoms from overproduction and accumulation of uric acid.
- Acute inflammatory syndrome: A paradoxical pro-inflammatory reaction with fever, arthralgias, arthritis, muscle pain and elevated inflammatory markers, without evidence of infection or underlying disease recurrence, has been reported, and some cases have resulted in hospitalization. Monitor when starting treatment or increasing the dosage. If it occurs, discontinue treatment and consider other treatment alternatives based on the risk and benefit for the patient.
- Hypersensitivity reactions: Postmarketing cases of hypersensitivity reactions, including angioedema and anaphylaxis, have been reported, generally within hours to the next day after initiating CellCept. If signs or symptoms occur, discontinue CellCept; treat and monitor until symptoms resolve.
- Immunizations: The use of live attenuated vaccines should be avoided during treatment, and patients should be advised that vaccinations may be less effective.
- Local reactions with rapid intravenous administration: CellCept Intravenous must not be given by rapid or bolus intravenous injection, because rapid infusion increases the risk of local adverse reactions such as phlebitis and thrombosis.
- Phenylketonuria: CellCept Oral Suspension contains aspartame, a source of phenylalanine (0.56 mg phenylalanine/mL suspension). Consider the combined daily amount of phenylalanine from all sources in a patient with PKU.
- Blood and semen donation: Patients should not donate blood during therapy and for at least 6 weeks after stopping. Based on animal data, men should not donate semen during therapy and for 90 days after stopping.
- Concomitant medications and MPA concentrations: A variety of drugs have potential to alter systemic MPA exposure. Measuring plasma MPA concentrations before and after changes to immunosuppressive therapy or concomitant medications may be appropriate.
- Impairment of ability to drive or operate machinery: CellCept may impact the ability to drive and use machines. Patients should avoid driving or using machines if they experience somnolence, confusion, dizziness, tremor, or hypotension.
Common Side Effects
The most common adverse reactions in clinical trials (20% or greater) include diarrhea, leukopenia, infection and vomiting. There is evidence of a higher frequency of certain types of infections, for example opportunistic infection.
Pregnancy: Use during pregnancy is associated with an increased risk of first trimester pregnancy loss and of congenital malformations, including external ear, eye, and other facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney, and nervous system. Consider alternative immunosuppressants with less potential for embryofetal toxicity. Females of reproductive potential should have a pregnancy test immediately before starting and 8 to 10 days later, and must use acceptable birth control during the entire therapy and for 6 weeks after stopping, unless the patient chooses abstinence. Sexually active male patients and/or their female partners should use effective contraception during treatment and for at least 90 days after.
Lactation: There are no data on the presence of mycophenolate in human milk; MPA is present in rat milk. Because available data are limited, it is not possible to exclude potential risks to a breastfeeding infant. Weigh the benefits of breastfeeding against the mother's clinical need for CellCept and any potential adverse effects on the infant.
Safety and effectiveness have been established in pediatric patients 3 months and older for the prophylaxis of organ rejection of allogenic kidney, heart or liver transplants.